Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

OBJECTIVE: To assess the safety and efficacy of ixekizumab, a monoclonal antibody that inhibits interleukin-17A, in a double-blind phase III trial enrolling patients with active psoriatic arthritis (PsA). METHODS: Patients naive to biologic therapy with active PsA were randomised to subcutaneous inj...

Descripción completa

Detalles Bibliográficos
Autores principales: Mease, Philip J, van der Heijde, Désirée, Ritchlin, Christopher T, Okada, Masato, Cuchacovich, Raquel S, Shuler, Catherine L, Lin, Chen-Yen, Braun, Daniel K, Lee, Chin H, Gladman, Dafna D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264219/
https://www.ncbi.nlm.nih.gov/pubmed/27553214
http://dx.doi.org/10.1136/annrheumdis-2016-209709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264219/
https://www.ncbi.nlm.nih.gov/pubmed/27553214
http://dx.doi.org/10.1136/annrheumdis-2016-209709

Ejemplares similares